New Preloaded System for Renal and Visceral Arteries in Fenestrated Endografting.

IF 1.7 2区 医学 Q3 PERIPHERAL VASCULAR DISEASE
Journal of Endovascular Therapy Pub Date : 2025-06-01 Epub Date: 2023-06-13 DOI:10.1177/15266028231179868
Enrico Gallitto, Gianluca Faggioli, Paolo Spath, Francesca M Feroldi, Rodolfo Pini, Antonino Logiacco, Gemmi Sufali, Stefania Caputo, Mauro Gargiulo
{"title":"New Preloaded System for Renal and Visceral Arteries in Fenestrated Endografting.","authors":"Enrico Gallitto, Gianluca Faggioli, Paolo Spath, Francesca M Feroldi, Rodolfo Pini, Antonino Logiacco, Gemmi Sufali, Stefania Caputo, Mauro Gargiulo","doi":"10.1177/15266028231179868","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim/background: </strong>The New Preloaded System (NPS) for renal/visceral arteries (TVVs) is an emerging technology in fenestrated endografting (FEVAR) that allows TVVs cannulation and stenting through the same access of the endograft main body. However, only few preliminary experiences are currently available in the literature. The aim of this study is to report the outcomes of NPS-FEVAR in juxta/para-renal (J/P-AAAs) and thoracoabdominal (TAAAs) aneurysms repair.</p><p><strong>Methods: </strong>This is a prospective (<i>NCT05224219</i>), single-center/observational study of patients submitted to NPS-FEVAR for J/PAAAs and TAAAs between 2019 and 2022 (July). Definitions and outcomes were evaluated according to the current SVS-reporting standard. Technical success (TS) and TS preloaded related, spinal cord ischemia (SCI), and 30-day mortality were assessed as early endpoints. Survival, freedom from reinterventions (FFRs), and freedom from TTVs-instability (FFTVVs-instability) were analyzed during follow-up.</p><p><strong>Results: </strong>Among 157 F/B-EVAR cases, 74 (47%) NPS-FEVAR were planned and enrolled in the study [48 (65%) J/P-AAAs; 26 (35%) TAAAs]. The main indication for NPS-FEVAR was the presence of a hostile iliac axis (54%-73%) or the necessity of expeditious pelvic/lower-limb reperfusion for SCI prevention in TAAAs (20%-27%). Overall, 292 TVVs were accommodated by 289 fenestrations and 3 branches; 188 of 289 (65%) fenestrations were preloaded. NPS-FEVAR configuration was from \"below\" and \"from below to above\" in 28 (38%) and 46 (62%) cases, respectively. TS and TS preloaded system-related was 96% (71/74) and 99% (73/74), respectively. Target visceral vessels patency at the completion angiography was 99% (290/292). Failures were 2 renal arteries loss and 1 massive bleeding from a percutaneous closure system breakage. The latter patient developed postoperative multiorgans failure and died on the fifth postoperative day, causing only 30-day/in-hospital mortality (1.3%). One (1.3%) patient with a JAAA and preoperative bilateral occlusion of the hypogastric arteries suffered SCI. The median follow-up was 14 (IQR: 8) months. The estimated 3-year survival was 91% with no aneurysm-related mortality during follow-up. The estimated 3-year FFR and FFTVVs-instability were 85 and 92%, respectively.</p><p><strong>Conclusion: </strong>New preloaded system FEVAR is a safe and effective option in the treatment of J/PAAAs and TAAAs in the presence of hostile iliac access or to guarantee an expeditious pelvic/lower limb reperfusion, leading to satisfactory results in terms of TS, early and mid-term clinical outcomes.Clinical ImpactNew preloaded system for fenestrated and branched endografting allows to increase the feasibility of the advanced endovascular aortic repair in challenging iliac access, thoracoabdominal aneurysm repair and reduce difficulties in target visceral vessels cannulation.</p>","PeriodicalId":50210,"journal":{"name":"Journal of Endovascular Therapy","volume":" ","pages":"669-678"},"PeriodicalIF":1.7000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Endovascular Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/15266028231179868","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/6/13 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

Abstract

Aim/background: The New Preloaded System (NPS) for renal/visceral arteries (TVVs) is an emerging technology in fenestrated endografting (FEVAR) that allows TVVs cannulation and stenting through the same access of the endograft main body. However, only few preliminary experiences are currently available in the literature. The aim of this study is to report the outcomes of NPS-FEVAR in juxta/para-renal (J/P-AAAs) and thoracoabdominal (TAAAs) aneurysms repair.

Methods: This is a prospective (NCT05224219), single-center/observational study of patients submitted to NPS-FEVAR for J/PAAAs and TAAAs between 2019 and 2022 (July). Definitions and outcomes were evaluated according to the current SVS-reporting standard. Technical success (TS) and TS preloaded related, spinal cord ischemia (SCI), and 30-day mortality were assessed as early endpoints. Survival, freedom from reinterventions (FFRs), and freedom from TTVs-instability (FFTVVs-instability) were analyzed during follow-up.

Results: Among 157 F/B-EVAR cases, 74 (47%) NPS-FEVAR were planned and enrolled in the study [48 (65%) J/P-AAAs; 26 (35%) TAAAs]. The main indication for NPS-FEVAR was the presence of a hostile iliac axis (54%-73%) or the necessity of expeditious pelvic/lower-limb reperfusion for SCI prevention in TAAAs (20%-27%). Overall, 292 TVVs were accommodated by 289 fenestrations and 3 branches; 188 of 289 (65%) fenestrations were preloaded. NPS-FEVAR configuration was from "below" and "from below to above" in 28 (38%) and 46 (62%) cases, respectively. TS and TS preloaded system-related was 96% (71/74) and 99% (73/74), respectively. Target visceral vessels patency at the completion angiography was 99% (290/292). Failures were 2 renal arteries loss and 1 massive bleeding from a percutaneous closure system breakage. The latter patient developed postoperative multiorgans failure and died on the fifth postoperative day, causing only 30-day/in-hospital mortality (1.3%). One (1.3%) patient with a JAAA and preoperative bilateral occlusion of the hypogastric arteries suffered SCI. The median follow-up was 14 (IQR: 8) months. The estimated 3-year survival was 91% with no aneurysm-related mortality during follow-up. The estimated 3-year FFR and FFTVVs-instability were 85 and 92%, respectively.

Conclusion: New preloaded system FEVAR is a safe and effective option in the treatment of J/PAAAs and TAAAs in the presence of hostile iliac access or to guarantee an expeditious pelvic/lower limb reperfusion, leading to satisfactory results in terms of TS, early and mid-term clinical outcomes.Clinical ImpactNew preloaded system for fenestrated and branched endografting allows to increase the feasibility of the advanced endovascular aortic repair in challenging iliac access, thoracoabdominal aneurysm repair and reduce difficulties in target visceral vessels cannulation.

开窗内移植术中新的肾和内脏动脉预载系统。
目的/背景:用于肾/内脏动脉(TVVs)的新型预载系统(NPS)是开窗内移植术(FEVAR)中的一项新兴技术,该技术允许通过同一通道的内移植物主体对TVVs进行插管和支架置入。然而,目前文献中只有很少的初步经验。本研究的目的是报道NPS-FEVAR在肾旁(J/P-AAAs)和胸腹(TAAAs)动脉瘤修复中的效果。方法:这是一项前瞻性(NCT05224219)、单中心/观察性研究,研究对象是2019年至2022年(7月)期间接受NPS-FEVAR治疗J/PAAAs和TAAAs的患者。定义和结果根据当前的svs报告标准进行评估。技术成功(TS)和TS预加载相关、脊髓缺血(SCI)和30天死亡率作为早期终点进行评估。在随访期间分析生存率、再干预自由度(FFRs)和ttvs -不稳定性自由度(fftvvs -不稳定性)。结果:157例F/B-EVAR中,74例(47%)NPS-FEVAR被纳入研究;26 (35%) taaa]。NPS-FEVAR的主要适应症是髂轴存在不良(54%-73%)或TAAAs患者需要快速骨盆/下肢再灌注以预防脊髓损伤(20%-27%)。289个开窗和3个分馆共容纳292台电视;289个开窗中有188个(65%)是预加载的。NPS-FEVAR配置分别为28例(38%)和46例(62%)为“从下到上”。TS和TS预加载系统相关性分别为96%(71/74)和99%(73/74)。完成血管造影时靶血管通畅度为99%(290/292)。失败包括2例肾动脉丢失和1例经皮闭合系统破裂导致大出血。后者出现术后多器官功能衰竭,于术后第5天死亡,仅造成30天/住院死亡率(1.3%)。1例(1.3%)术前双侧腹下动脉闭塞的JAAA患者发生脊髓损伤。中位随访时间为14 (IQR: 8)个月。估计3年生存率为91%,随访期间无动脉瘤相关死亡。估计3年FFR和fftvvs -不稳定性分别为85%和92%。结论:新型预载系统FEVAR是一种安全有效的治疗J/PAAAs和TAAAs的方法,可以保证骨盆/下肢快速再灌注,在TS、早期和中期临床结果方面取得令人满意的结果。新型开窗和分支腔内移植术预载系统提高了先进腔内主动脉修复在具有挑战性的髂通道、胸腹动脉瘤修复中的可行性,减少了目标内脏血管插管的困难。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.30
自引率
15.40%
发文量
203
审稿时长
6-12 weeks
期刊介绍: The Journal of Endovascular Therapy (formerly the Journal of Endovascular Surgery) was established in 1994 as a forum for all physicians, scientists, and allied healthcare professionals who are engaged or interested in peripheral endovascular techniques and technology. An official publication of the International Society of Endovascular Specialists (ISEVS), the Journal of Endovascular Therapy publishes peer-reviewed articles of interest to clinicians and researchers in the field of peripheral endovascular interventions.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信